الفهرس 
Lymphoproliferative DisordersOnly 14 pages are availabe for public view
 |  | from | 266 |  |  |
| | | from | 266 | | |
Abstract
Purpose To evaluate the impact of Hematopoietic stem cell transplantation on cardiac function of Egyptian patients with Lymphoproliferative disorders using non-invasive procedures, mainly echocardiography, and comparing it to classic chemotherapy regimens used without transplantation.
Patients and Methods 100 patients with Lymphoproliferative disorders who underwent transplantation in our stem cell transplant unit were included, they were first compared to a negative control group that involved participants without known cardiovascular disease, hypertension, or diabetes mellitus that were matched 1:1 based on age, sex and surface area to the cases. We then compared the cases to a positive control group in which we recruited 50 patients with Lymphoproliferative disorders who received chemotherapy without undergoing transplantation. A comparison of echocardiography study with doppler technique by a cardiologist who was blinded to clinical details of each subjects was done before and after transplantation by a period of 6 months; where a subclinical cardiac dysfunction was defined as fall of ejection fraction by more than or equal 15%. Ejection fraction was calculated by M-mode and modified Simpson′s formula. Intra-observer variability was reduced by taking the mean of three readings during each echocardiography.
Results 18% of cases who underwent bone marrow transplantation showed a subclinical cardiac dysfunction. Parameters which were found to have a significant correlation with ejection fraction decline included; age, sex, surface area, total body irradiation exposure, Lymphoproliferative disorder and the conditioning regimen used. 20% of the positive control group who received chemotherapy without undergoing transplantation showed a subclinical cardiac dysfunction. The healthy negative control had higher ejection fractions compared to the transplant cases.
Conclusion Pre-HCT exposure to anthracyclines & the conditioning-related therapeutic exposure are risks associated with cardiac affection after HCT. HCT may not cause major cardiac affection compared with prolonged use of cytoreductive agents.